Your fact-checks will appear here
Danish pharmaceutical company
President Trump publicly claimed extraordinarily large drug-price reductions — citing figures like “500%, 600%, 1,000%, 1,500%” — during July and August 2025 remarks and in subsequent events; fact‑che...
The Trump administration and its allies pursued a mix of executive actions, private-sector deals and agency directives that lowered some insulin costs for specific groups while leaving statutory caps ...
There is no credible reporting in the provided sources that President Trump “took $100 million from pharma” as a personal payment. The record in these documents shows aggressive White House pressure o...
Available reporting does not show Donald Trump personally investing his own money into pharmaceutical companies; instead, the Trump administration in 2025 pushed a set of deals and threatened tariffs ...
President Trump’s recent healthcare maneuvering centers on extending ACA premium subsidies for two years while proposing to send aid “directly to people,” plus executive actions on drug pricing and pr...
BurnPeak is marketed as a dietary supplement built on BHB ketone salts and plant extracts and claims appetite control and “natural fat-burning,” but available sources provide only marketing-style, unv...
Dr. Ania M. Jastreboff has authored peer‑reviewed reviews and clinical trial publications that situate GLP‑1 receptor agonists within modern obesity therapeutics and has led high‑profile clinical tria...
Pharmaceutical companies reacted to President Trump’s drug‑pricing campaign with a mix of public pushback, legal resistance to other federal price controls, and selectively cooperative deals that trad...
The Trump administration and White House fact sheets have frequently presented drug-price “reductions” as large percentage drops — including claims as high as “500%–1,500%” — but those numbers are mat...
The Trump 2025 administration pursued a two-track healthcare strategy: on one hand, and . Analysts, administration fact sheets, and partisan critics describe overlapping actions: negotiated manufactur...
Oprah Winfrey’s name has been connected to several health and diet product promotions that later drew regulatory scrutiny: most prominently Eli Lilly and Novo Nordisk received FDA warning letters tied...
A guest who fainted during a White House event announcing changes to weight‑loss drug access was initially misidentified online as a Novo Nordisk executive named “Gordon Findlay/Finlay,” but multiple ...
A medical emergency did occur in the Oval Office on November 6, 2025, when a man standing near President Trump collapsed during a press event about lowering weight‑loss drug costs; the White House Med...
As of 2025, the scientifically proven and FDA‑approved treatments for diabetes include multiple medication classes (insulins, GLP‑1 receptor agonists, GIP/GLP‑1 dual agonists, SGLT2 inhibitors, metfor...
The Trump administration issued multiple drug‑pricing directives in 2025 anchored by three executive orders and a campaign of MFN (most‑favored‑nation) negotiations and trade measures: an April 15, 20...
The FDA and state and private actors have recently escalated enforcement and oversight of compounded GLP‑1 and GIP/GLP‑1 products: federal warning letters numbering roughly 50–60 were posted in Septem...
Reports of deaths linked to weight‑loss drugs are documented in reputable reporting, but available sources show a mix of contexts — some deaths involve unlicensed or compounded copies, others are repo...
Bernie Sanders consistently champions aggressive government action to lower U.S. prescription drug prices, framing high prices as a moral crisis and pushing both legislative fixes and regulatory steps...
A medically related collapse occurred in the Oval Office on , during a White House event about lowering the cost of weight-loss drugs, when a guest associated with Eli Lilly fainted while standing beh...
Donald Trump’s recent drug-pricing deals hinge on direct manufacturer agreements, international reference pricing and targeted discounts for Medicare and Medicaid beneficiaries, whereas President Bide...